drugset / Trial / NCT00719381

Effect of Pioglitazone on Inflammation in Cystic Fibrosis

NCT00719381

Phase 1 Completed 24 enrolled Paul Beringer
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effect of pioglitazone on reducing airway inflammation in cystic fibrosis and characterize the amount and timecourse of pioglitazone elimination from the body.

Timeline

Start
2008-01
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pioglitazone Small molecule 30 mg

Indications